Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.65 USD
-0.01 (-0.60%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $1.64 -0.01 (-0.61%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 121 - 140 ( 274 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Corporate Update: Pipeline Focus in 2017 on RG-012 for Alport Syndrome; Reiterate OUTPERFORM and $6 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
March and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/FY16; Early Proof-of-Mechanism for RG-012 for Rare Alport Syndrome Could Be Achieved Before Year-End
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
February and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
RG-101 Could Be Lifted in Q1 2018 and We Look to Additional Pipeline Progress in 2017; Reiterate
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 30
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
January and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
R-D Day Highlights Expanding Clinical Pipeline; Reiterate OUTPERFORM and $13 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
December and Full Year 2017 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3 Update: Well Capitalized to Weather Minor Delays in Lead Programs; Reiterate OUTPERFORM but Reducing PT to $13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L